BioVie Inc - Ordinary Shares - Class A
BIVI
Market Cap$20.67M
Close$
$1.96
75.2% upside
Current Fair Value
75.2% upsideUndervalued by 75.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $20.67 Million |
|---|---|
| Enterprise Value | $-3,357,251.00 |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-3.56 |
| Beta | 1.18 |
| Outstanding Shares | 15,717,247 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.7 |
|---|---|
| PEG | 1.2 |
| Price to Sales | - |
| Price to Book Ratio | 1.12 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.13 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.11 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About BioVie Inc
3 employeesBioVie Inc. is developing BIV201 (continuous infusion terlipressin) an Orphan Drug candidate for the treatment of ascites due to advanced liver cirrhosis. First-to-market Orphan therapies typically receive 7 years of market exclusivity i...